Allgayer H, Heiss M M, Riesenberg R, Babic R, Jauch K W, Schildberg F W
Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilians University of Munich, Germany.
J Histochem Cytochem. 1997 Feb;45(2):203-12. doi: 10.1177/002215549704500206.
Phenotyping of cytokeratin (CK)18-positive cells in bone marrow is gaining increasing importance for future prognostic screening of carcinoma patients. Urokinase-type plasminogen activator receptor (uPA-R) is one example of a potential aggressive marker for those cells. However, a valid and reliable double staining method is needed. Using monoclonal antibodies against uPA-R and CK18, we modified an immunogold/alkaline phosphatase double staining protocol. UPA-R/CK18-positive tumor cell controls exhibited black uPA-R staining in 15-80% of cases and red CK18 staining in almost 100% of tumor cells. Isotype- and cross-matched controls were completely negative. Bone marrow from healthy donors was always CK18-negative. Reproducibility of CK18-positive cell detection was estimated in a series of specimens from 61 gastric cancer patients comparatively stained with the single alkaline phosphatase-anti-alkaline phosphatase (APAAP) and our double staining method (10(6) bone marrow cells/patient). In four cases, double staining could not reproduce CK18-positive cells. In 34 cases it revealed fewer or equal numbers, and in 23 cases more CK18-positive cells than the APAAP method. Overall quantitative analysis of detected cell numbers (838 in APAAP, range 1-280 in 10(6); double staining 808, range 0-253) demonstrated relative reproducibility of APAAP results by double staining of 97%. Correlation of results between both methods was significant (p < 0.001, linear regression). Sensitivity of double staining tested in logarithmic tumor cell dilutions was one CK18-positive cell in 300,000. Specific uPA-R staining was seen on CK18-positive cells in bone marrow from 29 of 61 patients, and also on single surrounding bone marrow cells. To test the specificity of this staining, bone marrow cytospins from 10 patients without tumor disease were stained for uPA-R with the APAAP method. uPA-R expression was confirmed in all 10 cases, with a mean of 6.5% uPA-R-positive cells in 1000 bone marrow cells (SEM 1.2%). These results suggest that our double staining protocol is a sensitive, reproducible, and specific method for routine uPA-R phenotyping of disseminated CK18-positive cells in bone marrow of carcinoma patients.
对骨髓中细胞角蛋白(CK)18阳性细胞进行表型分析,对于未来癌症患者的预后筛查愈发重要。尿激酶型纤溶酶原激活物受体(uPA-R)就是这些细胞潜在的侵袭性标志物之一。然而,需要一种有效且可靠的双重染色方法。我们使用抗uPA-R和CK18的单克隆抗体,对免疫金/碱性磷酸酶双重染色方案进行了改进。UPA-R/CK18阳性肿瘤细胞对照在15% - 80%的病例中呈现黑色uPA-R染色,几乎100%的肿瘤细胞呈现红色CK18染色。同型对照和交叉对照均为完全阴性。健康供者的骨髓始终为CK18阴性。在61例胃癌患者一系列标本中,比较碱性磷酸酶抗碱性磷酸酶(APAAP)单染色法和我们的双重染色法(每位患者10⁶个骨髓细胞),评估CK18阳性细胞检测的可重复性。4例中双重染色未能重现CK18阳性细胞。34例中显示的CK18阳性细胞数量少于或等于APAAP法,23例中多于APAAP法。对检测到的细胞数量进行总体定量分析(APAAP法838个,10⁶个细胞中范围为1 - 280个;双重染色法808个,范围为0 - 253个)表明,双重染色对APAAP结果的相对可重复性为97%。两种方法结果的相关性显著(p < 0.001,线性回归)。在对数肿瘤细胞稀释液中测试双重染色的敏感性为300,000个细胞中有1个CK18阳性细胞。在61例患者中,29例患者骨髓中CK18阳性细胞及部分周围单个骨髓细胞上可见特异性uPA-R染色。为测试该染色的特异性,用APAAP法对10例无肿瘤疾病患者的骨髓细胞涂片进行uPA-R染色。所有10例均证实有uPA-R表达,1000个骨髓细胞中uPA-R阳性细胞平均为6.5%(标准误1.2%)。这些结果表明,我们的双重染色方案是一种用于癌患者骨髓中播散性CK18阳性细胞常规uPA-R表型分析的敏感、可重复且特异的方法。